安罗替尼联合介入治疗原发性肝癌Ⅲ期患者的临床疗效

肝脏 ›› 2023, Vol. 28 ›› Issue (8): 928-931.

安罗替尼联合介入治疗原发性肝癌Ⅲ期患者的临床疗效

王春红, 冯巍巍, 张敬, 司晨菲

053000 河北省衡水市第三人民医院肿瘤科(王春红,冯巍巍),公共卫生科(张敬,司晨菲)

收稿日期:2023-04-26 出版日期:2023-08-31 发布日期:2023-09-21
基金资助:
河北省衡水市科技计划研究项目(20200140072)

A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy

WANG Chun-hong¹, FENG Wei-wei¹, ZHANG Jing², SI Chen-fei²

1. Department of Oncology,Hengshui Third People's Hospital, Hebei 053000, China;
2. Department of Public Health, Hengshui Third People's Hospital ,Hebei 053000, China

Received:2023-04-26 Online:2023-08-31 Published:2023-09-21

摘要/Abstract

摘要： 目的探讨肝动脉灌注化疗栓塞(TACE)联合安罗替尼治疗肝癌Ⅲ期的疗效。方法将2020年1月至2023年1月在衡水市第三人民医院接受治疗的205例肝癌Ⅲ期患者分组为对照组(103例)和观察组(102例)。两组患者行TACE后,观察组服用安罗替尼治疗,评价临床疗效。结果术后1个月,观察组Karnofsky评分(79.5±8.0)高于对照组(75.3±8.3)(P<0.05),观察组血清甲胎蛋白(AFP)和癌胚抗原(CEA)水平分别为(558. 82±49.87)ng/L和(33.89±5.45)ng/mL,均低于对照组的(611.34±45.56)ng/L和(43.78±5.23)ng/mL(P<0.05)。治疗后,观察组血清血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)、γ-谷氨酰转移酶(GGT)显著低于对照组(P<0.05);对照组疾病控制率为69.90%(72/103),观察组疾病控制率为88.23%(90/102)(χ²=11.959,P=0.008);对照组和观察组不良反应差异无统计学意义(P>0.05)。结论 TACE联合安罗替尼治疗肝癌晚期明显提高临床疗效,且不增加患者不良反应。

关键词: 原发性肝癌, 肝动脉化疗栓塞术, 安罗替尼, 临床效果

Abstract: Objective To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with arotinib on the treatment of stage III primary liver cancer.Methods 205 patients with stage III liver cancer who were treated in Hengshui Third People's Hospital from January 2020 to January 2023 were divided into a control group (n=103) and an observation group (n=102). After TACE therapy, patients in the observation group were administrated with arotinib and evaluated for the clinical efficacy.Results One month after surgery, the Karnofsky score was (79.5±8.0) in the observation group, which was higher than that of (75.3±8.3) in the control group (P<0.05). After treatment, the serum levels of alpha fetoprotein (AFP) and carcinoembryonic antigen (CEA) in the observation group were (558.82±49.87)ng/L and (33.89±5.45)ng/mL, respectively, which were significantly lower than those in the control group (P<0.05). Serum vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and γ-Glutamyle transferase (GGT) in the observation group were significantly lower than those in the control group (P<0.05); The disease control rate in the control group was 69.90%, while the disease control rate in the observation group was 88.23%, which was superior to the control group (χ²=11.959, P=0.008); There was no significant difference in adverse reactions between the control group and the observation group (P>0.05).Conclusion TACE combined with arotinib in the treatment of advanced liver cancer patients significantly improve clinical efficacy without increasing adverse reactions.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Arotinib, Clinical efficacy

王春红, 冯巍巍, 张敬, 司晨菲. 安罗替尼联合介入治疗原发性肝癌Ⅲ期患者的临床疗效[J]. 肝脏, 2023, 28(8): 928-931.

WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy[J]. Chinese Hepatolgy, 2023, 28(8): 928-931.

参考文献

[1] Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res,2019,49:14-32.
[2] Guo W,Chen S,Wu Z,et al.Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma:a retrospective study.Technol Cancer Res Treat,2020,19:15-33.
[3] Liu S,Qin T,Liu Z,et al.Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.Cell Death Dis,2020,11(5):309-318.
[4] Barz M,Gerhardt J,Bette S,et al.Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale-a bicentric retrospective study.BMC Neurol,2021,21:446-446.
[5] Sen A,Ryan PB,Goldstein A,et al.Correlating eligibility criteria generalizability and adverse events using big data for patients and clinical trials.Ann N Y Acad Sci,2017,1387:34-43.
[6] Chiu SH,Chang PY,Shih YL,et al.Efficacy and safety of supplemental transarterial chemoembolization through extrahepatic collateral arteries with drug-eluting beads:treatment for unresectable hepatocellular carcinoma.Drug Des Devel Ther,2020,14:5029-5041.
[7] Bucalau AM,Tancredi I,Verset G.In the Era of systemic therapy for hepatocellular carcinoma is transarterial chemoembolization still a card to play?Cancers,2021,13:5129-5138.
[8] Wang G,Sun M,Jiang Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor,suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.Int J Cancer,2019.,145:979-993.
[9] Song F,Hu B,Cheng JW,et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.Cell Death Dis,2020,11:573-573.
[10] Xie C,Wan X,Quan H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.Cancer Sci,2018,109:1207-1219.
[11] 陈思攀,杨耀博,焦阳,等.经导管动脉栓塞术联合小干扰核糖核酸治疗肝癌疗效及对兔缺氧诱导因子-1、血管内皮生长因子的影响.陕西医学杂志,2021,50(5):534-537,549.
[12] 文艺,张艳,龚星云,等.肝动脉灌注化疗栓塞后联合安罗替尼治疗中晚期肝癌临床疗效观察.中国冶金工业医学杂志,2021,38(6):627-628.
[13] Zhang A,Liu B,Xu D,et al.Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: a case report.Med,2019.98:184-195.
[14] 郭稳稳, 程昌盛, 吴燕,等. 安罗替尼联合肝动脉化疗栓塞术治疗晚期肝癌的疗效及对血清肿瘤相关因子的影响. 川北医学院学报, 2022(7):037.

[1]	李姣姣, 赵永昌, 武军霞. 原发性肝癌根治术后恶性胸腹水患者T淋巴细胞及NK细胞水平观察[J]. 肝脏, 2023, 28(8): 924-927.
[2]	胡志强, 门奋勇, 刘冬. 接受免疫检查点抑制剂治疗所致免疫相关不良事件与晚期原发性肝癌患者疗效的关联分析[J]. 肝脏, 2023, 28(8): 935-937.
[3]	李刚, 曹志群, 牛帅. 原发性肝癌根治性切除术后不同时间TACE对血清肿瘤标志物及复发风险的影响[J]. 肝脏, 2023, 28(7): 781-784.
[4]	陈永莹, 彭攀, 许磊磊. SVM预测模型在原发性肝癌病理分化程度判断中的应用[J]. 肝脏, 2023, 28(7): 785-788.
[5]	郭丹丹, 覃岭, 高文峰, 袁春旺, 张英华, 张永宏. 血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析[J]. 肝脏, 2023, 28(6): 665-667.
[6]	赵喜君, 杨宁. 肿瘤异质性在原发性肝癌中的研究进展[J]. 肝脏, 2023, 28(5): 515-517.
[7]	许正锯, 刘会国, 颜燕燕, 叶巧霞, 张小曼, 黄进发, 李勇飞, 吴金票. 原发性肝癌微波消融术后对血清高尔基体蛋白73、甲胎蛋白的影响[J]. 肝脏, 2023, 28(5): 554-558.
[8]	朱烨晨, 耿承军, 殷慧康, 李亚南, 冯权烨. MIP及VR三维重建在原发性肝癌TACE介入前血管系统评估中的应用[J]. 肝脏, 2023, 28(5): 559-563.
[9]	范芯铷, 刘铭佳, 王庆, 汪慧. 原发性肝癌的发病机制及治疗进展[J]. 肝脏, 2023, 28(4): 391-392.
[10]	秦晓平, 张静, 艾平. 血清TREM-1、sCD163及sB7-H3检测在原发性肝癌患者中的表达[J]. 肝脏, 2023, 28(4): 461-464.
[11]	郭丹丹, 张英华, 高文峰, 生守鹏, 张永宏. 肝豆状核变性相关原发性肝癌的临床特征分析[J]. 肝脏, 2023, 28(3): 290-292.
[12]	刘二丽, 李博群, 黄盈婷, 崔号, 汪晓军, 章红英. 原发性肝癌四种治疗策略的成本效果比较[J]. 肝脏, 2023, 28(2): 193-199.
[13]	柴晓哲, 朱霞峰, 王少峰, 骆成林. 白蛋白-胆红素评分联合血氨检测对原发性肝癌切除术后并发肝性脑病的预测价值[J]. 肝脏, 2022, 27(9): 994-998.
[14]	马军伟, 柳计强, 宋冉. IVIM扩散加权成像在氩氦刀冷冻治疗原发性肝癌中的作用[J]. 肝脏, 2022, 27(7): 778-781.
[15]	周成香, 刘亚斌, 苏红, 蒋怡香, 林海燕. 肝脏超声造影对原发性肝癌微波消融术后血供状态评估的价值[J]. 肝脏, 2022, 27(6): 637-639.